Skip to main content

Table 2 The best overall response (N = 42) in patients treated with biweekly SOX

From: Biweekly oxaliplatin plus S1 for Chinese elderly patients with advanced gastric or gastroesophageal junction cancer as the first-line therapy: a single-arm, phase 2 study

The best response (N = 42)

No. (%)

CR

0 (0%)

PR

22 (52.5%)

SD

14 (33.3%)

PD

6 (14.3%)

ORR (CR + PR)

22 (52.5%)

DCR (CR + PR + SD)

36 (85.7%)

  1. CR Complete response, PR Partial response, SD Stable disease, PD Progressive disease, ORR Objective response rate, DCR Disease control rate